Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary
Abstract Introduction Approval of the anti‐amyloid monoclonal antibodies has stimulated an important discussion of the value to be placed on the magnitude of slowing achieved by treatment compared to placebo. Methods The minimal clinically important difference (MCID) was reviewed in the context of o...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Online Access: | https://doi.org/10.1002/trc2.12411 |